A Randomized Study to Evaluate the Safety, Tolerability and Antiviral Activity of ABT-450, ABT-333 and ABT-072
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
This study assessed the safety, tolerability, pharmacokinetics, and antiviral activity of
multiple oral doses of ABT-450/ritonavir (r), ABT-333 (also known as dasabuvir), or ABT-072
in hepatitis C virus (HCV), genotype 1-infected, treatment-naïve adults.